The rising popularity of weightloss drugs like Wegovy, Ozempic, Semaglutide have been considered to have the potential to end the issue of obesity around the world. These drugs, which were originally produced for treatment of diabetes, require a weekly injection to lead to a potential 15% loss of body weight. These drugs come particularly at a time in which obesity rates are on the rise, such that the World Obesity Federation says that by 2035 more than half the world’s population (or 4 billion people) could be considered overweight or obese. However, questions around their long-term costs, both in financial and health terms, arise.

James Murray speaks with Professor Ian Caterson, Foundation Director of The Boden Collaboration for Obesity Nutrition Exercise and Eating Disorders, Boden Professor of Human Nutrition at The University of Sydney, and a past President of the World Obesity Federation.